Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. An ADC combines the specificity of an antibody and the potent power of an anti?cancer cancer agent or disease-relevant toxin. necks inhibiting these first?generation
Let's personalize your content